Plain-English translation of NCT06795893 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a monitoring program for women with lupus who are pregnant or planning to become pregnant while taking . Researchers will collect detailed information about your pregnancy, delivery, and your baby's health during the first year of life to make sure the medication is safe during pregnancy and does not harm the developing baby or newborn.
Lupus is an autoimmune disease that often affects women of childbearing age, and doctors need to understand whether —a newer treatment for lupus—is safe to use during pregnancy. This program will gather real-world information to help doctors and patients make informed decisions about treatment during pregnancy.
You likely qualify if…
You likely don't qualify if…
You will share information about your pregnancy, delivery, and your baby's health at key times: around the time of delivery and again 12 months after your baby is born. The research team will collect this information from reports you or your doctor submit, and may ask follow-up questions to ensure they have complete details. If your pregnancy has already ended when you join, you will provide information once; if you join while still pregnant, you will be contacted again after delivery.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
Sweden
AstraZeneca
Collaborators
PPD Development, LP
Enrollment target
~240 participants
Started
November 2025
Primary completion
April 2031
Sex
Female only
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
AstraZeneca Clinical Study Information Center
PPD Miami, US
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.